Amyloid Beta-peptide (25-35) (human) Mechanisms, Research Ap

Amyloid Beta-peptide (25-35) (human): Mechanisms, Research Applications, and Clinical Relevance in Neurodegenerative Disease Models

Introduction
Amyloid Beta-peptide (25-35) (human), commonly abbreviated as Aβ(25-35), is a synthetic peptide fragment derived from the C-terminal region of the full-length amyloid beta (Aβ) peptide. The Aβ peptide itself is a cleavage product of the amyloid precursor protein (APP) and is centrally implicated in the pathogenesis of Alzheimer’s disease (AD) and related neurodegenerative disorders (Selkoe, 2001, *Physiol Rev*). The Aβ(25-35) fragment, comprising amino acids 25 to 35 of the full-length peptide, is widely used in experimental neuroscience due to its robust neurotoxicity and ability to recapitulate key features of amyloid-induced cellular dysfunction in vitro and in vivo (Yankner et al., 1990, *Science*). Mechanistically, Aβ(25-35) exerts its effects through the induction of oxidative stress, mitochondrial dysfunction, and the promotion of apoptotic pathways in neuronal cells. Unlike the full-length Aβ(1-42) or Aβ(1-40), Aβ(25-35) is more soluble, readily forms aggregates, and retains the neurotoxic properties characteristic of amyloid peptides, making it a practical and reliable tool for modeling amyloid toxicity in laboratory settings (Pike et al., 1995, *J Neurochem*). This research paper provides a comprehensive overview of Aβ(25-35), focusing on its clinical value, research applications, challenges addressed, supporting literature, experimental data, usage guidelines, and future research directions.

[Related: baflomycin] Clinical Value and Applications
The clinical value of Aβ(25-35) lies primarily in its utility as a research tool rather than a therapeutic agent. Its principal application is in the modeling of Alzheimer’s disease and other neurodegenerative conditions characterized by amyloid pathology. By mimicking the neurotoxic effects of amyloid accumulation, Aβ(25-35) enables researchers to investigate the molecular mechanisms underlying neuronal death, synaptic dysfunction, and the role of oxidative stress in disease progression (Kowall et al., 1992, *Proc Natl Acad Sci USA*). Aβ(25-35) is extensively used in: - **In vitro studies**: To induce neurotoxicity in cultured neuronal and glial cells, facilitating the screening of neuroprotective compounds and elucidation of cellular pathways involved in amyloid toxicity. - **In vivo models**: Intracerebral or intraventricular administration in rodents produces cognitive deficits and neuropathological changes reminiscent of AD, supporting preclinical evaluation of candidate drugs and therapeutic interventions (Maurice et al., 1996, *Neuroscience*). - **Mechanistic studies**: To dissect the roles of oxidative stress, mitochondrial dysfunction, calcium dysregulation, and apoptosis in amyloid-induced neurodegeneration. [Related: blebbistatin] The peptide’s ability to rapidly induce pathological features relevant to AD makes it a valuable surrogate for longer, more complex amyloid peptides in experimental systems, thereby accelerating the pace of discovery in neurodegenerative disease research.

Key Challenges and Pain Points Addressed
Current models of Alzheimer’s disease and related disorders face several challenges, including the lengthy time required for pathology to develop in transgenic animals, variability in amyloid aggregation, and the complexity of full-length Aβ peptides. Aβ(25-35) addresses several of these pain points: - **Rapid induction of pathology**: Aβ(25-35) aggregates quickly and induces neurotoxicity within hours to days, enabling efficient experimental timelines (Pike et al., 1995). - **Reproducibility**: The short, defined sequence and robust aggregation properties of Aβ(25-35) reduce batch-to-batch variability, enhancing reproducibility across studies. - **Cost-effectiveness**: Synthesis and handling of Aβ(25-35) are more straightforward compared to longer amyloid peptides, reducing costs and technical barriers. - **Simplification of mechanistic studies**: The peptide’s potent and consistent neurotoxic effects facilitate the dissection of cellular pathways without the confounding factors present in more complex models. [Related: aprotinin structure] Despite these advantages, it is important to recognize that Aβ(25-35) is a fragment and may not fully recapitulate all aspects of amyloid pathology observed in human disease. Nonetheless, it remains an indispensable tool for hypothesis-driven research and preclinical drug screening.

Literature Review
Several key studies have established the relevance and utility of Aβ(25-35) in neurodegenerative disease research: 1. **Yankner et al. (1990, Science)**: This seminal study demonstrated that Aβ(25-35) is highly neurotoxic to cultured hippocampal neurons, establishing its use as a model for amyloid-induced neurodegeneration. The authors showed that the peptide induces cell death via mechanisms involving oxidative stress and calcium dysregulation. 2. **Pike et al. (1995, J Neurochem)**: Pike and colleagues compared the neurotoxic properties of various Aβ fragments, finding that Aβ(25-35) is as potent as full-length peptides in inducing neuronal death. The study highlighted the fragment’s rapid aggregation and its suitability for in vitro neurotoxicity assays. 3. **Kowall et al. (1992, Proc Natl Acad Sci USA)**: This study provided in vivo evidence that intracerebral injection of Aβ(25-35) in rats leads to neuronal loss and gliosis, mirroring key features of AD pathology. The findings validated the use of Aβ(25-35) in animal models for preclinical research. 4. **Maurice et al. (1996, Neuroscience)**: Maurice and colleagues demonstrated that Aβ(25-35) administration in rodents impairs learning and memory, supporting its use in behavioral studies of cognitive dysfunction and drug screening. 5. **Butterfield et al. (2002, J Neurochem)**: This review summarized the oxidative mechanisms of Aβ(25-35) toxicity, emphasizing its role in lipid peroxidation, protein oxidation, and mitochondrial impairment, all of which are central to AD pathogenesis. 6. **Stefanova et al. (1998, Neurochem Int)**: The authors investigated the effects of antioxidants on Aβ(25-35)-induced neurotoxicity, providing evidence for the involvement of reactive oxygen species and supporting the peptide’s use in screening neuroprotective agents. 7. **Klementiev et al. (2007, J Neurosci Res)**: This study explored the anti-inflammatory and neuroprotective effects of various compounds against Aβ(25-35)-induced toxicity, further validating the peptide’s utility in drug discovery. Collectively, these studies underscore the scientific value of Aβ(25-35) as a model system for elucidating the molecular underpinnings of amyloid toxicity and for the preclinical evaluation of candidate therapeutics.

Experimental Data and Results
Experimental studies employing Aβ(25-35) consistently demonstrate its capacity to induce hallmark features of neurodegeneration: - **Cellular toxicity**: Exposure of primary neuronal cultures or neuroblastoma cell lines to micromolar concentrations of Aβ(25-35) results in dose-dependent cell death, characterized by apoptotic morphology, DNA fragmentation, and activation of caspases (Yankner et al., 1990; Pike et al., 1995). - **Oxidative stress**: Aβ(25-35) treatment elevates levels of reactive oxygen species (ROS), lipid peroxidation products (e.g., malondialdehyde), and protein carbonyls, indicating oxidative damage (Butterfield et al., 2002). - **Mitochondrial dysfunction**: The peptide disrupts mitochondrial membrane potential, impairs ATP production, and triggers the release of cytochrome c, linking amyloid toxicity to energy failure and apoptosis (Stefanova et al., 1998). - **In vivo pathology**: Intracerebral injection of Aβ(25-35) in rodents leads to neuronal loss, gliosis, and cognitive deficits in maze-based learning tasks (Kowall et al., 1992; Maurice et al., 1996). - **Therapeutic screening**: Antioxidants, anti-inflammatory agents, and neurotrophic factors have been shown to mitigate Aβ(25-35)-induced toxicity, validating the peptide’s use in drug discovery pipelines (Klementiev et al., 2007). These findings confirm that Aβ(25-35) is a robust and reliable agent for modeling amyloid-induced neurodegeneration and for evaluating the efficacy of candidate neuroprotective interventions.

Usage Guidelines and Best Practices
To ensure reproducibility and reliability in experimental studies utilizing Aβ(25-35), the following guidelines are recommended: - **Preparation**: Aβ(25-35) should be dissolved in sterile distilled water or phosphate-buffered saline (PBS) to a stock concentration (commonly 1–2 mM). To promote aggregation, the peptide is often incubated at 37°C for 24–48 hours prior to use. - **Concentration**: Typical working concentrations range from 10 to 50 μM for in vitro studies, depending Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 58 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11497020